Bacteria, notably Pseudomonas aeruginosa, are assumed to be the most important cause of respiratory exacerbations in patients with cystic fibrosis.' 2 The incidence of viral and mycoplasma infections has not been convincingly shown to be higher in patients with cystic fibrosis than in healthy controls,34 but the consequences of these infections may be more serious.46 Consequently, it is generally recommeded that patients with cystic fibrosis should be immunised against influenza.67 Despite extensive investigation, however, some 20% of the respiratory exacerbations in these patients may not be associated with any of the common bacteria or viruses.8 Legionella pneumophila, which has a predilection for patients who are debilitated9 or suffer from chronic lung disease,'0 is a plausible cause of respiratory deterioration in patients with cystic fibrosis. Apart from a preliminary report from Philadelphia in which a stable population of patients with cystic fibrosis was screened for antibodies against L pneumophila as a single epidemiological observation," almost nothing is known of the role of Address for reprint requests: Dr J Efthimiou, Department of Thoracic Medicine, University College Hospital, London WC1E 6AU.
Accepted I November 1983 this bacterium in cystic fibrosis. The present study was undertaken to investigate the role of viruses and L pneumophila in the acute respiratory exacerbations of young adults with cystic fibrosis.
Patients and methods
Forty six patients with cystic fibrosis (25 male, 21 female) with a mean age of 22-2 years (range 16-41 years) were studied for evidence of infection with viruses, L pneumophila, Mycoplasma pneumoniae, Coxiella burnetii, and Chlamydia psittaci, as well as for the usual bacterial pathogens. Both culture and serological methods were used.
The patients were the first 46 seen in the cystic fibrosis clinic at the Brompton Hospital from January to April 1980. All patients had had a uniform pattern of attendance at the clinic (monthly or more frequent) before the initial study visit. The patients were classified as either "deteriorated" or "stable." The deteriorated group consisted of 24 patients in whom an increase in cough, sputum production or breathlessness was accompanied by an FEV, at least 15% less than the value obtained at a preliminary visit one month before. The Significantly fewer patients in our stable group had serological evidence of non-bacterial infection, sug- There was no significant difference between the different groups (X2 test).
this study. Other types of antigen have produced false positive results with adenovirus'2 and mycoplasma'6 infections in the past. This incidence of 17-4% with demonstrable titres of L pneumophila antibody in our study contrasts signficantly with 3-4% in a population of 502 randomly selected blood donors'7 and with 3-8% in a group of 1378 patients with respiratory illness not due to legionnaires' disease. '7 In at least three of the eight patients with antibody titres of 1/32 or more infection with L pneumophila was strongly suggested. In one of these the antibody titres rose from less than 1/16 to 1/64 during the study and were accompanied by a respiratory illness responsive to treatment with erythromycin. We believe that this is the first time an L pneumophila infection has been confirmed in a patient with cystic fibrosis. Two other patients in whom the L pneumophila antibody titres showed a fourfold reduction, from 1/128 one year before the present study to < 1/16 at the end of the study, had both had a respiratory illness consistent with legionnaires' disease. These two patients may have been recovering from L pneumophila infection between the pilot study and the present one. Immunosuppressants, including corticosteroids, are thought to be predisposing factors in legionnaires' disease'8 19 but they did not explain the high incidence of demonstrable L pneumophila antibody titres in our patients. In a study of 41 patients with asthma 20% had raised titres of antibody against L pneumophila.'0 There appeared to be no relationship between the presence of raised antibody titres and corticosteroid treatment.
Possibly therefore there is a higher incidence of infection with L pneumophila in patients with cystic fibrosis than in healthy controls. Alternative explanations for the demonstrable L pneumophila antibody titres might include overactivity of the immune system, reflected by raised immunoglobulin concentrations,20 an increased prevalence ofAspergillus fumigatus precipitins,2' or simply an anamnestic response. Serological cross reactivity between L pneumophila and P aeruginosa has been recorded (M Collins et al, paper presented to the 11th European Working Group on Cystic Fibrosis, Brussels, 1982) , which is of interest as P aeruginosa was the principal bacterial pathogen in the sputum of all eight patients with L pneumophila antibody titres of 1/32 or more. Serological cross reactivity may not be the whole explanation, however, as the other 29 patients chronically infected with P aeruginosa (table 3) did not have demonstrable titres of antibody against L pneumophila. The possibility that some of the demonstrable L pneumophila antibody titres detected in this study are the result of exposure to some other viral or bacterial antigen that cross reacts with L pneumophila cannot be excluded.
We are uncertain why there were no patients with indirect fluorescent antibody titres of 1/32 or more one year after the initial visit whereas there were eight patients in this category one month after it. Possibly the results reflect a minor epidemic of L pneumophila infection, although there was no increase in the reporting of raised indirect fluorescent antibody titres in other patients in the hospital, who were suffering from a wide variety of lung disease, at the time of the initial visit. Perhaps a proportion of the patients with indirect fluorescent antibody titres of 1/32 or more were showing an anamnestic reaction in the course of an acute respiratory illness. But even if this were the explanation of the raised titres, it is difficult to explain why there were more of these exacerbations at the beginning of the study than a year later, although most of the 46 patients were in fact stable one year later. We can find no reason to question the constancy of the assay method used to detect antibodies against L pneumophila in this study, particularly as the same assay showed patients without cystic fibrosis to have raised indirect fluorescent antibody titres during the period of the study, and there do not appear to have been any missed cases of legionnaires' disease during this time. If patients with cystic fibrosis are indeed more susceptible to infection with L pneumophila than normal people, then it is still necessary to explain whether this is due to their chronic ill health and underlying lung disease, to impaired immunological defences, or simply to increased exposure.
Bacteria, notably P aeruginosa, are the main pathogens in patients with cystic fibrosis. Viral, mycoplasma, coxiella, and legionella infections, however, may be associated with up to a third of the acute exacerbations of respiratory disease in young adults with cystic fibrosis. These organisms, in addition to the usual bacteria, should be sought and treatment instituted where appropriate.
